<DOC>
	<DOCNO>NCT02562326</DOCNO>
	<brief_summary>This double-blind , randomise , control , two-period crossover phase Ib trial use individualised standard meal fix nutrient ratio subject type 2 diabetes mellitus investigate post-prandial blood glucose control BioChaperone insulin lispro compare insulin lispro ( Humalog® , Eli Lilly Company ) period multiple daily dose administration 14 day . Each subject randomise sequence two treatment , either BioChaperone insulin lispro-Humalog® Humalog®-BioChaperone insulin lispro . Injections take place immediately individualised standard meal morning day 1 , 2 , 13 , 14 . Insulin dos determine screen visit . During outpatient phase subject keep basal insulin constant ( except change safety reason ) . They self-measure blood glucose least 4 time daily ( pre-prandial bedtime ) . In addition , two day per outpatient period ( Day 5 9 ) blood glucose measure 7 time daily ( pre-prandial , 2 hour post-prandial bedtime ) .</brief_summary>
	<brief_title>A Trial Investigate Efficacy , Pharmacokinetics , Safety Tolerability BioChaperone Insulin Lispro Comparison Humalog® U-100 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Type 2 diabetes mellitus ≥ 12 month Treated stable multiple daily insulin ≥ 3 month ( basalbolus therapy bolus insulin therapy ) Current total daily insulin treatment &lt; 1.2 ( I ) U/kg/day Body Mass Index equal 40.0 kg/m² HbA1c ≤ 9.0 % local laboratory analysis Known suspect hypersensitivity trial product relate product Type 1 diabetes mellitus Previous participation trial The receipt investigational product within 60 day prior trial Clinically significant abnormal haematology , biochemistry , lipid , urinalysis screening test , judge Investigator consider underlying disease Presence clinically significant acute gastrointestinal symptom ( e.g . nausea , vomit , heartburn diarrhoea ) , judge Investigator Presence renal impairment ( Estimated Glomerular filtration Rate ( eGFR ) &lt; 60 milliliters/minute/1.73m² ) Presence late diabetic complication and/or acute coronary heart disease . Known slow gastric empty gastrointestinal surgery opinion investigator might change gastrointestinal motility food absorption Unusual meal habit special diet requirement unwillingness eat food provide trial Current treatment corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>